VBI Vaccines, Inc. – (NASDAQ:VBIV) was the recipient of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 788,524 shares, a growth of 51.2% from the February 15th total of 521,575 shares. Currently, 6.6% of the company’s stock are short sold. Based on an average daily trading volume, of 147,408 shares, the days-to-cover ratio is presently 5.3 days.
VBI Vaccines (NASDAQ:VBIV) opened at $3.94 on Wednesday. The company has a quick ratio of 5.26, a current ratio of 5.32 and a debt-to-equity ratio of 0.10. VBI Vaccines has a 12 month low of $3.04 and a 12 month high of $6.60. The stock has a market cap of $259.05, a price-to-earnings ratio of -5.40 and a beta of 1.62.
Several equities analysts recently commented on VBIV shares. BMO Capital Markets initiated coverage on VBI Vaccines in a report on Wednesday, November 15th. They issued an “outperform” rating and a $11.00 target price on the stock. BidaskClub downgraded shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, Zacks Investment Research upgraded shares of VBI Vaccines from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Saturday, December 23rd. Three research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $8.75.
COPYRIGHT VIOLATION WARNING: This story was published by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://weekherald.com/2018/03/14/short-interest-in-vbi-vaccines-inc-vbiv-rises-by-51-2.html.
About VBI Vaccines
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.